This article was originally published in The Gray Sheet
Executive SummaryCompletes a $6.2 mil. equity funding via the issuance of 560,000 shares of series B preferred stock in exchange for $2 mil. in cash and the retirement of $4.2 mil. in convertible debentures. The Tampa, Florida-based manufacturer of specialty surgical products and provider of tissue processing services says the cash funds will be used for the completion of a new U.S. tissue processing facility. Each share of the series B preferred stock will entitle its holder "to receive 8.5% cumulative cash dividends, payable quarterly, and to convert into common stock at $1.10 per share" the company says. As a result of the financing, Biodynamics" series A convertible preferred shareholders will be able to convert their stock into common stock at $1.25 per share. The firm retains an option to redeem the series B stock after three years for 120% of its issue price
You may also be interested in...
Agency hasn't named the celebrity that will participate in the study on the impact that celebrity and non-celebrity endorsements have on consumer perceptions about Rx drugs.
Chronicle of the development and review of Sarepta’s golodirsen for treatment of Duchenne muscular dystrophy patients with a genetic mutation amenable to exon 53 skipping.
ODE I director Ellis Unger chafed at the notion of approving the Duchenne muscular dystrophy drug golodirsen on the same unvalidated surrogate marker, this time in the face of infection and renal toxicity concerns; OND’s Peter Stein granted Sarepta’s appeal while also calling attention to the company’s failure to timely conduct the eteplirsen confirmatory trial.